Safety and clinical efficacy of toripalimab, a PD-1 mAb, in patients with advanced or recurrent malignancies in a phase I study

医学 不利影响 耐火材料(行星科学) 内科学 临床研究阶段 毒性 实体瘤疗效评价标准 加药 淋巴瘤 肺癌 外科 胃肠病学 物理 天体生物学
作者
Jianliang Yang,Lihou Dong,Sheng Yang,Xiaohong Han,Ying Han,Shiyu Jiang,Jiarui Yao,Zhishang Zhang,Shuxiang Zhang,Peng Liu,Yan Qin,Hai Wu,Hui Feng,Sheng Yao,Yan Ping Sun,Haifeng Song,Yuankai Shi
出处
期刊:European Journal of Cancer [Elsevier BV]
卷期号:130: 182-192 被引量:72
标识
DOI:10.1016/j.ejca.2020.01.028
摘要

Purpose This is a first-in-human phase I study investigating the safety and efficacy of toripalimab, a humanized monoclonal antibody against the programmed cell death-1 (PD-1) receptor, in Chinese patients with advanced or recurrent malignant tumor refractory to standard treatment. Patients and methods During dose escalation, patients received a single-dose intravenous infusion of toripalimab for 56 days followed by multidose infusions every two weeks. The planned dosing groups were 1, 3 and 10 mg/kg. During dose expansion, patients received toripalimab every two weeks. Clinical response was evaluated by investigators every 6 weeks. Results Thirty-three patients were enrolled, including 12 patients with alveolar soft part sarcoma (ASPS), seven with non–small-cell lung cancer and 11 with lymphoma. Patients were heavily pretreated with a median of 3 prior lines of systemic treatments. Toripalimab was well tolerated without dose-limiting toxicity. All patients experienced treatment-related adverse events. Grade 3 and above treatment-related adverse events occurred in six (18.2%) patients. Among 22 solid tumors, the objective response rate (ORR) was 22.7% per RECIST v1.1. The ORR was 90.9% in 11 lymphoma patients per IWG 2007. The median duration of response was 21.5 months. The median progression-free survival was 5.7 months for solid tumors and 8.3 months for lymphomas. The median OS was not reached for all patients and the lymphoma subgroups. The median OS was 34.7 months for patients with ASPS. Conclusion Toripalimab was well tolerated up to 10 mg/kg Q2W without dose-limiting toxicity and showed promising and durable antitumour activities in patients with ASPS and lymphoma, who were heavily pretreated. Clinical trial information ClinicalTrials.gov Identifier: NCT02836834.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
畅快安白完成签到,获得积分10
1秒前
2秒前
吴硫完成签到,获得积分10
2秒前
过时的南烟完成签到,获得积分10
2秒前
3秒前
今天不熬夜完成签到 ,获得积分10
3秒前
叁月二完成签到 ,获得积分10
5秒前
锅锅完成签到 ,获得积分10
5秒前
春夏秋冬完成签到,获得积分10
5秒前
枫糖叶落完成签到,获得积分10
6秒前
luoluo完成签到,获得积分20
7秒前
啊哈完成签到 ,获得积分10
8秒前
9秒前
波哥发布了新的文献求助10
10秒前
典雅浩轩完成签到,获得积分10
11秒前
gaga完成签到,获得积分10
11秒前
帅帅完成签到,获得积分10
12秒前
吕小布完成签到,获得积分10
13秒前
孤独的问柳完成签到,获得积分10
13秒前
1113完成签到 ,获得积分10
15秒前
地狱跳跳虎完成签到 ,获得积分10
16秒前
针尖上的王子完成签到,获得积分10
16秒前
有延迟完成签到 ,获得积分10
16秒前
CDI和LIB完成签到,获得积分10
16秒前
sdfwsdfsd完成签到,获得积分10
17秒前
lym完成签到,获得积分10
17秒前
爆米花的应助被1437594843采纳,获得10
18秒前
wizard完成签到,获得积分10
20秒前
小肚黄完成签到 ,获得积分10
21秒前
cmaz完成签到 ,获得积分10
21秒前
笑点低的项链完成签到 ,获得积分10
21秒前
明天完成签到,获得积分10
23秒前
ccccchen完成签到,获得积分10
23秒前
发发旦旦完成签到,获得积分10
23秒前
marine完成签到 ,获得积分10
24秒前
小福完成签到 ,获得积分10
25秒前
不除庭草完成签到 ,获得积分10
26秒前
丰富的大地完成签到,获得积分10
26秒前
愉快惮的应助被哎呀我去采纳,获得10
28秒前
隐形曼青的应助被科研通管家采纳,获得10
28秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8159131
求助须知:如何正确求助?哪些是违规求助? 9554607
关于积分的说明 21719828
捐赠科研通 7748795
什么是DOI,文献DOI怎么找? 3427149
关于科研通互助平台的介绍 2552079
邀请新用户注册赠送积分活动 2471428